Pay in 4 interest-free payments of $7.26 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Key benefits Why people compare it 1 14.9% mean body weight reduction demonstrated in STEP 1 trial (N=1,961) 2 20% reduction in major adverse cardiovascular events in SELECT trial (N=17,604) 3 Significant reduction in appetite and food cravings via hypothalamic POMC/CART activation 4 Improved glycemic control with glucose-dependent insulin secretion potentiation 5 Once-weekly dosing enabled by 165-hour plasma half-life and albumin binding 6 86.4% of STEP 1 participants achieved at least 5% body weight loss 7 Demonstrated NAFLD/NASH improvement with reduction in liver fat content 8 Well-characterized safety profile from over 30,000 participants across STEP and SELECT programs Deep research Semaglutide (chemical name: N-epsilon26-[2-(2-[2-(2-[2-(2-((S)-2-carboxy-3-((1S,2R)-3-carboxy-1-(carboxymethyl-carbamoyl)-propylcarbamoyl)-propionylamino)-ethoxy)-ethoxy)-acetylamino]-ethoxy)-ethoxy)-acetyl]-[Aib8,Arg34]-GLP-1-(7-37)-peptide) is a 39-amino-acid peptide with a molecular weight of 4,113.58 Da
It cannot lawfully be sold for human administration or compounded under U.S
Studies have found GLP-1RA discontinuation rates of 36%81% in the first year of treatment
10.22358/jafs/65719/2014 38
US$ 29.05
US$ 22.27
US$ 29.01
